AB2 Bio

Switzerland
Malters, Lucerne, Switzerland, CH-1015

Company profile

AB2 Bio company profile

AB2 Bio Ltd located at the innovation park of the école polytechnique fédérale de lausanne (epfl), is a drug discovery and development company focused on developing “best in class” innovative therapies for the treatment of inflammatory diseases with large unmet medical needs inflammation is a natural defense mechanism. However, dysregulated and persistent inflammatory processes are the basis of several chronic inflammatory and autoimmune diseases, such as: nlrc4 - mas, adult onset still's disease, chronic obstructive pulmonary disease and many others ab2 bio is developing drugs that will not only treat the symptoms but also target the underlying causes of inflammation-based diseases extensive phase i and ib clinical trials demonstrated a high tolerance and an excellent safety profile of their drug. They have advanced clinical programs in nlrc4 mas and in adult onset still’s disease.

Business identity

Contact email
[email protected]
Phone number
+41216938280
Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Revenue range
$0-$1M
Founded
2010-01-01, Year

Headquarters

Postal code
CH-1015
Country code
CH
Continent
Europe

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
1
Total equity funding
$57.7M
Last funding
Series B / $57.7M / 2016-01-14
Last equity funding
Series B / $57.7M
Founders
2
Articles
12

Founders and investors

Founders

Avinoam KadouriBarthelemy Helg